142 related articles for article (PubMed ID: 35641286)
21. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
Sacdalan DB; Lucero JA
Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
[TBL] [Abstract][Full Text] [Related]
22. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
23. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
[TBL] [Abstract][Full Text] [Related]
25. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
[TBL] [Abstract][Full Text] [Related]
26. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
[TBL] [Abstract][Full Text] [Related]
28. Alectinib for ALK-positive non-small-cell lung cancer.
Rossi A
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
[TBL] [Abstract][Full Text] [Related]
29. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
30. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
31. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.
Sato J; Nakano K; Shimizu T; Uchida M
Anticancer Res; 2022 Jul; 42(7):3575-3582. PubMed ID: 35790278
[TBL] [Abstract][Full Text] [Related]
33. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
34. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.
Fujita S; Masago K; Katakami N; Yatabe Y
J Thorac Oncol; 2016 Jun; 11(6):e67-72. PubMed ID: 26751586
[TBL] [Abstract][Full Text] [Related]
35. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
36. Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up.
Pruis MA; Veerman GDM; Hassing HC; Lanser DAC; Paats MS; van Schaik RHN; Mathijssen RHJ; Manintveld O; Dingemans AC
JACC CardioOncol; 2023 Feb; 5(1):102-113. PubMed ID: 36875894
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Komada F
Yakugaku Zasshi; 2018; 138(2):229-235. PubMed ID: 29386436
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database.
Sato J; Eren T; Murata S; Shimizu T; Uchida M
Anticancer Res; 2022 Dec; 42(12):5917-5925. PubMed ID: 36456140
[TBL] [Abstract][Full Text] [Related]
40. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]